Company intelligence / Profile preview

GenieBiome

Hong Kong, Hong Kong

Ownership: Private
Development stage: Other

Overview

The company has commercialized evidence-based microbiome-based diagnostics (e.g., for colorectal cancer and autism) and clinically validated live biotherapeutic and synbiotic products for liver and gut health among Asian populations, supported by studies such as a clinical trial with 27 patients in MAFLD demonstrating reduction in liver scarring and improvements in metabolism and inflammation[6].

Therapeutic areas: DermatologyPsychiatryInfectious DiseasesMetabolic DisordersOncology
Modalities: Live biotherapeutic product therapyMicrobial therapyDiagnosticDevice
Industry: Biotech

Partnerships

Faculty of Medicine, The Chinese University of Hong Kong

Beyond the preview

Go deeper on GenieBiome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenieBiome.

Explore the full profile